FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313646317> ?p ?o ?g. }

• W4313646317 endingPage "830" @default.
• W4313646317 startingPage "823" @default.
• W4313646317 abstract "Abstract Background Primary axillary hyperhidrosis (PAHH) strongly affects the patient's quality of life. To date, topical treatment options are limited. One percent glycopyrronium bromide (GPB) showed promising efficacy and safety in a pivotal 4‐week Phase 3a study. Objectives To assess efficacy and safety of topical 1% GPB cream in patients with severe PAHH in a long‐term study of 72 weeks versus baseline. Methods This was a long‐term, open‐label, Phase 3b trial for 72 weeks including 518 patients with severe PAHH. Patients were treated with 1% GPB cream once daily for 4 weeks, followed by a flexible dosing scheme (min. twice per week, max. once daily). Primary endpoint was the absolute change in sweat production from baseline to week 12. Further study endpoints included assessment of the severity of PAHH and the impact on quality of life. Results Total median sweat production decreased by 119.30 mg (−65.6%, both median) until week 12. Absolute change in sweat production from baseline to week 12 in logarithmic values was statistically significant ( p < 0.0001). Patients' quality of life was improved at all study time points compared to baseline, as assessed by Hyperhidrosis Quality of Life Index and Dermatology Life Quality Index ( p < 0.0001). Treatment was safe and locally well‐tolerated with only few mild to moderate adverse drug reactions (ADRs). Dry mouth and application site erythema were the most common reported ADRs. Conclusions Treatment with 1% GPB cream over 72 weeks significantly reduces sweat production and improves quality of life in patients with severe PAHH. One percent GPB cream is well‐tolerated and provides an effective treatment option for long‐term use in patients with severe PAHH." @default.
• W4313646317 created "2023-01-07" @default.
• W4313646317 creator A5002640669 @default.
• W4313646317 creator A5006330750 @default.
• W4313646317 creator A5026891613 @default.
• W4313646317 creator A5037879330 @default.
• W4313646317 creator A5042514351 @default.
• W4313646317 creator A5066827550 @default.
• W4313646317 creator A5074182324 @default.
• W4313646317 creator A5081683872 @default.
• W4313646317 creator A5086628287 @default.
• W4313646317 creator A5089019058 @default.
• W4313646317 date "2023-01-31" @default.
• W4313646317 modified "2023-10-17" @default.
• W4313646317 title "Long‐term efficacy and safety of 1% glycopyrronium bromide cream in patients with severe primary axillary hyperhidrosis: Results from a Phase 3b trial" @default.
• W4313646317 cites W1964742133 @default.
• W4313646317 cites W2070027959 @default.
• W4313646317 cites W2072943191 @default.
• W4313646317 cites W2096991001 @default.
• W4313646317 cites W2142380008 @default.
• W4313646317 cites W2143031888 @default.
• W4313646317 cites W2161218938 @default.
• W4313646317 cites W2507750354 @default.
• W4313646317 cites W2512802730 @default.
• W4313646317 cites W2884190070 @default.
• W4313646317 cites W2889619184 @default.
• W4313646317 cites W2923002834 @default.
• W4313646317 cites W2945095562 @default.
• W4313646317 cites W2949873078 @default.
• W4313646317 cites W3033383030 @default.
• W4313646317 cites W3082375167 @default.
• W4313646317 cites W3090885284 @default.
• W4313646317 cites W3107088870 @default.
• W4313646317 cites W3116030348 @default.
• W4313646317 cites W3123909043 @default.
• W4313646317 cites W3165631791 @default.
• W4313646317 cites W3194103164 @default.
• W4313646317 cites W4317779874 @default.
• W4313646317 doi "https://doi.org/10.1111/jdv.18843" @default.
• W4313646317 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36606529" @default.
• W4313646317 hasPublicationYear "2023" @default.
• W4313646317 type Work @default.
• W4313646317 citedByCount "0" @default.
• W4313646317 crossrefType "journal-article" @default.
• W4313646317 hasAuthorship W4313646317A5002640669 @default.
• W4313646317 hasAuthorship W4313646317A5006330750 @default.
• W4313646317 hasAuthorship W4313646317A5026891613 @default.
• W4313646317 hasAuthorship W4313646317A5037879330 @default.
• W4313646317 hasAuthorship W4313646317A5042514351 @default.
• W4313646317 hasAuthorship W4313646317A5066827550 @default.
• W4313646317 hasAuthorship W4313646317A5074182324 @default.
• W4313646317 hasAuthorship W4313646317A5081683872 @default.
• W4313646317 hasAuthorship W4313646317A5086628287 @default.
• W4313646317 hasAuthorship W4313646317A5089019058 @default.
• W4313646317 hasBestOaLocation W43136463171 @default.
• W4313646317 hasConcept C126322002 @default.
• W4313646317 hasConcept C141071460 @default.
• W4313646317 hasConcept C159110408 @default.
• W4313646317 hasConcept C16005928 @default.
• W4313646317 hasConcept C168563851 @default.
• W4313646317 hasConcept C197934379 @default.
• W4313646317 hasConcept C203092338 @default.
• W4313646317 hasConcept C2776173921 @default.
• W4313646317 hasConcept C2777288759 @default.
• W4313646317 hasConcept C2778650131 @default.
• W4313646317 hasConcept C2779121184 @default.
• W4313646317 hasConcept C2779951463 @default.
• W4313646317 hasConcept C2780564577 @default.
• W4313646317 hasConcept C42219234 @default.
• W4313646317 hasConcept C63398376 @default.
• W4313646317 hasConcept C71924100 @default.
• W4313646317 hasConceptScore W4313646317C126322002 @default.
• W4313646317 hasConceptScore W4313646317C141071460 @default.
• W4313646317 hasConceptScore W4313646317C159110408 @default.
• W4313646317 hasConceptScore W4313646317C16005928 @default.
• W4313646317 hasConceptScore W4313646317C168563851 @default.
• W4313646317 hasConceptScore W4313646317C197934379 @default.
• W4313646317 hasConceptScore W4313646317C203092338 @default.
• W4313646317 hasConceptScore W4313646317C2776173921 @default.
• W4313646317 hasConceptScore W4313646317C2777288759 @default.
• W4313646317 hasConceptScore W4313646317C2778650131 @default.
• W4313646317 hasConceptScore W4313646317C2779121184 @default.
• W4313646317 hasConceptScore W4313646317C2779951463 @default.
• W4313646317 hasConceptScore W4313646317C2780564577 @default.
• W4313646317 hasConceptScore W4313646317C42219234 @default.
• W4313646317 hasConceptScore W4313646317C63398376 @default.
• W4313646317 hasConceptScore W4313646317C71924100 @default.
• W4313646317 hasIssue "4" @default.
• W4313646317 hasLocation W43136463171 @default.
• W4313646317 hasLocation W43136463172 @default.
• W4313646317 hasOpenAccess W4313646317 @default.
• W4313646317 hasPrimaryLocation W43136463171 @default.
• W4313646317 hasRelatedWork W2051842182 @default.
• W4313646317 hasRelatedWork W2087566648 @default.
• W4313646317 hasRelatedWork W2125335815 @default.
• W4313646317 hasRelatedWork W2345070986 @default.
• W4313646317 hasRelatedWork W2412820421 @default.
• W4313646317 hasRelatedWork W2771084125 @default.

• next